Dissecting spatiotemporal heterogeneity of glioblastoma evolution under therapy

Active Grant Awarded

Award ID
R00CA286730
Recipient
Awarding agency
Obligated
$248,999

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 20% complete
Place of performance
Miami, FL 33136, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The Translational Genomics Research Institute, doing business as Tgen Research Institute, $248,999 obligated under Grant R00CA286730 on April 10, 2026, through the Cancer Biology Research program (CFDA 93.396). The award is classified as a Grant assistance type.

The award funds research dissecting the spatiotemporal heterogeneity of glioblastoma evolution under therapy. Aim 1 develops a multiomics-based network diffusion approach to identify protein and phospho-protein subnetworks affected by upstream genetic events that drive neuronal programs during progression. That work includes in silico knockout network screens and integrative analysis of proteomics and pharmacological data. The project also applies proteogenomics and single-nuclei RNA sequencing profiling to matched primary and recurrent IDH wild-type glioblastoma tumors.

Performance runs from the April 10, 2026 award date to an ultimate completion date of March 31, 2029, with place of performance in Miami, Florida 33136. The Cancer Biology Research program supports fundamental research on the cause and nature of cancer, with the expectation that this yields better methods of prevention, detection, diagnosis, and treatment of neoplastic diseases. Its listed research areas include tumor biology and metastasis and cancer cell biology.

Description

Abstract
Glioblastoma (GBM) is an uncurable form of primary brain tumor with extremely poor prognosis. Despite multi- modal therapy including surgery, irradiation and chemotherapy, all patients experience tumor progression. No standard of care is established in recurrent or progressive GBM. The identification of a neuronal cellular state of GBM as a more differentiated state enriched at recurrence and periphery of the tumor provides new insights into how neuronal activity regulates tumor invasion. Deconvolution of normal cell types from single-cell rnaseq and bulk tumors revealed that neuronal state of GBM is associated with high infiltration of non-malignant cells. The intricate synaptic communications between neurons and brain tumor cells are crucial for glioma progression and resistance to standard therapies, which is supported by ample data from the rapidly emerging field of "cancer neuroscience". However, the molecular mechanisms driving enhanced neuronal activity at recurrence remains to be understood. Dissecting the spatiotemporal dynamics of glioma ECO-system during evolution will be necessary to identify therapeutic vulnerability of recurrent GBM. Here, proteogenomics and single-nuclei rnaseq profiling of matched primary and recurrent GBM IDH wild-type suggest that the evolutionary transition from a more proliferative-progenitor towards the neuronal state in GBM is regulated by both genetic and post- genetic molecular events and potential functional interactions between malignant and non-malignant cells. In aim 1, the development of a multiomics-based network diffusion approach will enlighten subnetworks of proteins/phospho-proteins significantly affected by upstream genetic events driving activation of neuronal programs during progression. Generation of in silico knock-out networks screen and integrative analysis of proteomics and pharmacological data of cancer cell lines will prioritize lethal and essential proteins in the subnetworks to identify potential therapeutic vulnerabilities in neuronal-recurrent GBM. In aim 2, single-nuclei and spatial transcriptomics profiling of matched primary and recurrent GBM IDH wild-type will identify the functional connections between neurodevelopmental tumor cellular states and cell types in tumor microenvironment. The development of a spatial informed cell-cell communications algorithm and the reconstruction of intercellular signaling networks will infer the key functional interactions between neurodevelopmental tumor cellular states and cell types in tumor microenvironment along with the potential effect of these interactions on downstream regulatory molecular pathways. These studies lay the foundation for my future research program and will advance the understanding of the molecular mechanisms mediating glioma connectomes and driving glioma invasion. These studies will advance the neuroscience field through discovery of targetable pathways and proteins providing therapeutic opportunities for recurrent GBM.

Quick answers

Who received award R00CA286730?

R00CA286730 was awarded to The Translational Genomics Research Institute by National Cancer Institute (National Institutes of Health) on April 10, 2026.

How much is award R00CA286730 worth?

$248,999 has been obligated on R00CA286730.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award